Suppr超能文献

糖原磷酸化酶抑制剂N-叠氮乙酰基-β-D-吡喃葡萄糖胺的晶体学研究:与N-乙酰基-β-D-吡喃葡萄糖胺的比较。

Crystallographic studies on N-azidoacetyl-beta-D-glucopyranosylamine, an inhibitor of glycogen phosphorylase: comparison with N-acetyl-beta-D-glucopyranosylamine.

作者信息

Petsalakis Evangelia I, Chrysina Evangelia D, Tiraidis Costas, Hadjiloi Theodoros, Leonidas Demetres D, Oikonomakos Nikos G, Aich Udayanath, Varghese Babu, Loganathan Duraikkannu

机构信息

Institute of Organic and Pharmaceutical Chemistry, The National Hellenic Research Foundation, 48, Vas. Constantinou Ave., 116 35 Athens, Greece.

出版信息

Bioorg Med Chem. 2006 Aug 1;14(15):5316-24. doi: 10.1016/j.bmc.2006.03.044. Epub 2006 Apr 17.

Abstract

N-acetyl-beta-D-glucopyranosylamine (NAG) is a potent inhibitor (Ki=32 microM) of glycogen phosphorylase b (GPb), and has been employed as a lead compound for the structure-based design of new analogues, in an effort to utilize its potential as a hypoglycaemic agent. Replacement of the acetamido group by azidoacetamido group resulted in an inhibitor, N-azidoacetyl-beta-D-glucopyranosylamine (azido-NAG), with a Ki value of 48.7 microM, in the direction of glycogen synthesis. In order to elucidate the mechanism of inhibition, we determined the ligand structure in complex with GPb at 2.03 A resolution, and the structure of the fully acetylated derivative in the free form. The molecular packing of the latter is stabilized by a number of bifurcated hydrogen bonds of which the one involving a bifurcated C-H...N...H-C type hydrogen bonding is rather unique in organic azides. Azido-NAG can be accommodated in the catalytic site of T-state GPb at approximately the same position as that of NAG and stabilizes the T-state conformation of the 280 s loop by making several favourable contacts to residues of this loop. The difference observed in the Ki values of the two analogues can be interpreted in terms of desolvation effects, subtle structural changes of protein residues and changes in water structure.

摘要

N-乙酰-β-D-吡喃葡萄糖胺(NAG)是糖原磷酸化酶b(GPb)的一种有效抑制剂(抑制常数Ki = 32微摩尔),已被用作基于结构设计新类似物的先导化合物,以发挥其作为降血糖剂的潜力。用叠氮乙酰氨基取代乙酰氨基得到一种抑制剂,N-叠氮乙酰-β-D-吡喃葡萄糖胺(叠氮-NAG),其抑制常数Ki值为48.7微摩尔,朝着糖原合成的方向。为了阐明抑制机制,我们以2.03埃的分辨率测定了与GPb结合的配体结构,以及游离形式的完全乙酰化衍生物的结构。后者的分子堆积通过许多分叉氢键得以稳定,其中涉及分叉C-H...N...H-C型氢键的那个在有机叠氮化物中相当独特。叠氮-NAG可以在与NAG大致相同的位置容纳在T态GPb的催化位点,并通过与该环的残基形成几个有利的接触来稳定280 s环的T态构象。两种类似物在抑制常数Ki值上观察到的差异可以用去溶剂化效应、蛋白质残基的细微结构变化和水结构的变化来解释。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验